Proton therapy developer Ion Beam Applications (IBA) has sold its RadioMed unit to IZI Medical Products for an estimated price of $14 million to $16 million.
RadioMed, which IBA acquired in 2003, makes Visicoil, an implantable fiducial marker for soft-tissue tumor localization designed to enhance the accuracy of radiation therapy planning and delivery. IZI develops, manufactures, and provides medical consumable devices for interventional radiology and oncology, radiation therapy, neuro-spine, and image-guided surgery procedures.
IBA will retain ownership of the rest of its dosimetry products and business.
